A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations
Kidney disease caused by type 1 diabetes can progress to end stage renal disease and can increase mortality risk. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) plays a major role in producing oxidative stress in the kidney in diabetes, and its activity is attenuated by GKT137831, an oral Nox inhibitor with predominant inhibitory action on Nox-1 and Nox − 4. Previous studies have demonstrated renoprotective effects with GKT137831 in various experimental models of type 1 diabetes-related kidney disease.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Anne T. Reutens, Karin Jandeleit-Dahm, Merlin Thomas, Leon A. Bach, Peter G. Colman, Timothy M.E. Davis, Michael D'Emden, Elif I. Ekinci, Greg Fulcher, Peter Shane Hamblin, Mark A. Kotowicz, Richard J. MacIsaac, Claire Morbey, David Simmons, Georgia Solda Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 1 | Endocrinology | Georgia Health | Radiology | Statistics | Study | Urology & Nephrology